Evidence map›Paper›PMID 32534153›Full record

ArticleMatrix biology : journal of the International Society for Matrix Biology2020

Significance of host heparanase in promoting tumor growth and metastasis.

Gan-Lin Zhang, Lilach Gutter-Kapon, Neta Ilan, Tahira Batool, Kailash Singh, Andreas Digre, Zhengkang Luo, Stellan Sandler, Yuval Shaked, Ralph D Sanderson and 3 more

Open access · greenAbstract read
In one paragraph

Article in Matrix biology : journal of the International Society for Matrix Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Unlocking the Anti-Breast Cancer Potential ofCurrent issues in molecular biology · 2025
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Induction of heparanase 2 (Hpa2) expression by stress is mediated by ATF3.Matrix biology : journal of the International Society for Matrix Biology · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Frontiers in immunology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

Gan-Lin ZhangOncology Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China; Department of Medical Biochemistry and Microbiology, SciLifeLab Uppsala, The Biomedical Center, University of Uppsala, Uppsala, Sweden.
Lilach Gutter-KaponTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, P. O. Box 9649, Technion, Haifa 31096, Israel.
Neta IlanTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, P. O. Box 9649, Technion, Haifa 31096, Israel.
Tahira BatoolDepartment of Medical Biochemistry and Microbiology, SciLifeLab Uppsala, The Biomedical Center, University of Uppsala, Uppsala, Sweden.
Kailash SinghDepartment of Cell Biology, University of Uppsala, Uppsala, Sweden.
Andreas DigreDepartment of Medical Biochemistry and Microbiology, SciLifeLab Uppsala, The Biomedical Center, University of Uppsala, Uppsala, Sweden.
Zhengkang LuoDepartment of Cell Biology, University of Uppsala, Uppsala, Sweden.
Stellan SandlerDepartment of Cell Biology, University of Uppsala, Uppsala, Sweden.
Yuval ShakedTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, P. O. Box 9649, Technion, Haifa 31096, Israel.
Ralph D SandersonDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Xiao-Min WangOncology Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China. Electronic address: wangxiaomin_bhtcm@126.com.
Jin-Ping LiOncology Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China; Department of Medical Biochemistry and Microbiology, SciLifeLab Uppsala, The Biomedical Center, University of Uppsala, Uppsala, Sweden. Electronic address: jin-ping.li@imbim.uu.se.
Israel VlodavskyTechnion Integrated Cancer Center, Rappaport Faculty of Medicine, P. O. Box 9649, Technion, Haifa 31096, Israel. Electronic address: Vlodavsk@mail.huji.ac.il.
Technion – Israel Institute of Technology · ILUppsala University · SEScience for Life Laboratory · SEUppsala University Hospital · SECapital Medical University · CNUniversity of Alabama at Birmingham · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Heparanase in Tumor Progression, Metastasis and ChemoresistanceR01CA211752 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SANDERSON, RALPH D · 2017 to 2021
$1.7M
NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA211752
6 · The paper itself

Abstract

Heparanase, the sole heparan sulfate degrading endoglycosidase, regulates multiple biological activities that enhance tumor growth, angiogenesis and metastasis. Much of the impact of heparanase on tumor progression is related to its function in mediating tumor-host crosstalk, priming the tumor microenvironment to better support tumor growth and metastasis. We have utilized mice over-expressing (Hpa-tg) heparanase to reveal the role of host heparanase in tumor initiation, growth and metastasis. While in wild type mice tumor development in response to DMBA carcinogenesis was restricted to the mammary gland, Hpa-tg mice developed tumors also in their lungs and liver, associating with reduced survival of the tumor-bearing mice. Consistently, xenograft tumors (lymphoma, melanoma, lung carcinoma, pancreatic carcinoma) transplanted in Hpa-tg mice exhibited accelerated tumor growth and shorter survival of the tumor-bearing mice compared with wild type mice. Hpa-tg mice were also more prone to the development of metastases following intravenous or subcutaneous injection of tumor cells. In some models, the growth advantage was associated with infiltration of heparanase-high host cells into the tumors. However, in other models, heparanase-high host cells were not detected in the primary tumor, implying that the growth advantage in Hpa-tg mice is due to systemic factors. Indeed, we found that plasma from Hpa-tg mice enhanced tumor cell migration and invasion attributed to increased levels of pro-tumorigenic factors (i.e., RANKL, SPARC, MIP-2) in the plasma of Hpa-Tg vs. wild type mice. Furthermore, tumor aggressiveness and short survival time were demonstrated in wild type mice transplanted with bone marrow derived from Hpa-tg but not wild type mice. These results were attributed, among other factors, to upregulation of pro-tumorigenic (i.e., IL35

Indexed as

Up-RegulationAnimalsAnthracenesCell Line, TumorCell MovementGene Expression Regulation, NeoplasticGlucuronidaseHeparanaseHumansMiceMice, TransgenicNeoplasm MetastasisNeoplasmsNeoplasm TransplantationPiperidinesTumor Microenvironment3-(2,6-bis(4-fluorophenyl)-3-methylpiperidin-4-ylideneamino)-2-thioxoimidazolidin-4-one on 7,12-dimethylbenz(a)anthraceneAnthracenesGlucuronidaseHeparanasePiperidinesHeparanaseHost factorsImmune cellsMetastasisTumor microenvironment

Identifiers

PMID32534153
PMCPMC7704762
OpenAlexW3034514717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.